MA39481A - Thérapies ciblées - Google Patents
Thérapies cibléesInfo
- Publication number
- MA39481A MA39481A MA039481A MA39481A MA39481A MA 39481 A MA39481 A MA 39481A MA 039481 A MA039481 A MA 039481A MA 39481 A MA39481 A MA 39481A MA 39481 A MA39481 A MA 39481A
- Authority
- MA
- Morocco
- Prior art keywords
- targeted therapies
- therapies
- targeted
- Prior art date
Links
- 238000002626 targeted therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461947108P | 2014-03-03 | 2014-03-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA39481A true MA39481A (fr) | 2015-09-11 |
Family
ID=54055980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA039481A MA39481A (fr) | 2014-03-03 | 2015-03-03 | Thérapies ciblées |
Country Status (10)
Country | Link |
---|---|
US (2) | US10232049B2 (fr) |
EP (1) | EP3129064B1 (fr) |
JP (2) | JP6576942B6 (fr) |
KR (1) | KR20160126078A (fr) |
CN (1) | CN106456795A (fr) |
AU (1) | AU2015224576A1 (fr) |
CA (1) | CA2941618A1 (fr) |
IL (1) | IL247624A0 (fr) |
MA (1) | MA39481A (fr) |
WO (1) | WO2015134464A2 (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3131586A4 (fr) * | 2014-03-18 | 2017-10-25 | Madrigal Pharmaceuticals, Inc. | Agents thérapeutiques cibles |
FI3660004T3 (fi) | 2016-10-11 | 2023-05-04 | Arvinas Operations Inc | Yhdisteitä ja menetelmiä androgeenireseptorin kohdennettuun hajotukseen |
AU2018289354A1 (en) * | 2017-06-20 | 2020-01-02 | Tva (Abc), Llc | Combination therapies comprising targeted therapeutics |
IL299893A (en) * | 2017-06-20 | 2023-03-01 | Madrigal Pharmaceuticals Inc | prescribed medications |
CN110799194A (zh) * | 2017-06-20 | 2020-02-14 | 马德里加尔制药公司 | 包含靶向治疗剂的联合疗法 |
CN109512821B (zh) * | 2017-09-18 | 2021-06-08 | 无锡富泽药业有限公司 | 一种克唑替尼与17-aag复合聚合物纳米胶束注射剂、其制备方法及其应用 |
CA3085759A1 (fr) * | 2017-12-14 | 2019-06-20 | Tarveda Therapeutics, Inc. | Conjugues ciblant hsp90 et formulations de ces derniers |
WO2019232366A1 (fr) * | 2018-06-01 | 2019-12-05 | Tarveda Therapeutics, Inc. | Polythérapie |
CN109575044A (zh) * | 2018-12-21 | 2019-04-05 | 西安交通大学 | 2-(喜树碱-10-氧基)乙酰胺类化合物和应用 |
DK3935068T3 (da) | 2019-03-06 | 2023-12-04 | Propella Therapeutics Inc | Abirateron-prodrugs |
KR20220008869A (ko) | 2019-05-14 | 2022-01-21 | 누베이션 바이오 인크. | 항암 핵 호르몬 수용체-표적화 화합물 |
CN110003181B (zh) * | 2019-05-22 | 2020-08-28 | 北京凯恩梅格医药科技有限公司 | 一种基于克唑替尼结构的c-Met/HDAC双靶点抑制剂及其合成方法与应用 |
CN111499623B (zh) * | 2020-04-01 | 2022-07-08 | 南京缘聚医药科技有限公司 | 一类非核苷抗肿瘤药物的噻唑酮脲衍生物及其药物用途 |
JP2024504932A (ja) | 2021-01-13 | 2024-02-02 | モンテ ローザ セラピューティクス, インコーポレイテッド | イソインドリノン化合物 |
US11957696B2 (en) | 2021-02-15 | 2024-04-16 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
EP4313991A1 (fr) | 2021-03-23 | 2024-02-07 | Nuvation Bio Inc. | Composés ciblant des récepteurs hormonaux nucléaires anticancéreux |
CN117580839A (zh) | 2021-05-03 | 2024-02-20 | 诺维逊生物股份有限公司 | 抗癌核激素受体靶向化合物 |
CN114933584B (zh) * | 2021-08-09 | 2022-12-27 | 上海贵之言医药科技有限公司 | 一种二氢-2h-异吲哚酯类化合物 |
CN115650975A (zh) * | 2022-08-23 | 2023-01-31 | 四川大学华西医院 | 一种靶向降解人表皮生长因子受体2的蛋白降解靶向嵌合体化合物及其应用 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
WO1999061055A1 (fr) | 1998-05-22 | 1999-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Molecules bifonctionnelles et therapies basees sur celles-ci |
US8617514B2 (en) | 1999-02-22 | 2013-12-31 | Georgetown University | Tumor-targeted nanodelivery systems to improve early MRI detection of cancer |
EP1169319A4 (fr) | 1999-04-09 | 2005-02-09 | Sloan Kettering Institutefor C | Procedes et compositions permettant la degradation et/ou l'inhibition des tyrosine kinases appartenant a la famille her |
AU2877202A (en) | 2000-11-02 | 2002-05-15 | Sloan Kettering Inst Cancer | Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors |
US7671010B2 (en) | 2002-08-30 | 2010-03-02 | The Board Of Regents Of The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
EP1519735A4 (fr) | 2001-12-12 | 2006-01-11 | Conforma Therapeutic Corp | Essais et mises en oeuvre permettant de determiner et de moduler une activite de liaison hsp90 |
GB0211578D0 (en) | 2002-05-21 | 2002-06-26 | Univ Belfast | Medicaments |
US6759416B2 (en) | 2002-08-06 | 2004-07-06 | Panorama Research, Inc. | Anticancer conjugates of camptothecin and unsaturated fatty acids |
US7769423B2 (en) | 2002-09-11 | 2010-08-03 | Duke University | MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting |
AU2003303058A1 (en) | 2002-12-12 | 2004-07-09 | Conforma Therapeutics Corporation | Cytotoxins and diagnostic imaging agents comprising hsp90 ligands |
WO2005095347A1 (fr) | 2004-03-26 | 2005-10-13 | Van Andel Research Institute | Geldanamycine et ses derives pouvant inhiber une proliferation cancereuse et identifier de nouvelles cibles |
NZ555158A (en) | 2004-11-18 | 2010-09-30 | Synta Pharmaceuticals Corp | Triazole compounds that modulate Hsp90 activity |
WO2006084030A2 (fr) | 2005-02-01 | 2006-08-10 | Sloan-Kettering Institute For Cancer Research | Petites molecules inhibitrices du hsp90 |
WO2007053792A2 (fr) | 2005-11-05 | 2007-05-10 | Amplyx Pharmaceuticals, Inc. | Amelioration des proprietes pharmacocinetiques d'inhibiteurs de proteases et d'autres medicaments |
CA2632903C (fr) | 2005-12-02 | 2015-11-24 | Vianova Labs, Inc. | Traitement du cancer et d'autres maladies |
GB0526615D0 (en) | 2005-12-30 | 2006-02-08 | Novartis Ag | Organic compounds |
TWI490212B (zh) | 2006-05-25 | 2015-07-01 | Synta Pharmaceuticals Corp | 調節hsp90活性之三唑化合物 |
JP5599610B2 (ja) | 2006-06-30 | 2014-10-01 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Hsp90の阻害による神経変性疾患の処置 |
JP5721949B2 (ja) | 2006-10-12 | 2015-05-20 | アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited | 複合薬剤 |
WO2008057246A2 (fr) | 2006-10-26 | 2008-05-15 | Synta Pharmaceuticals Corp. | Procédé de traitement de troubles inflammatoires |
EP2133094A4 (fr) | 2007-03-05 | 2010-10-13 | Kyowa Hakko Kirin Co Ltd | Composition pharmaceutique |
US20120003160A1 (en) | 2007-06-29 | 2012-01-05 | Amag Pharmaceuticals, Inc. | Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session |
US20100203114A1 (en) | 2007-07-09 | 2010-08-12 | Warf - Wisconsin Alumni Research Foundation | Micelle encapsulation of therapeutic agents |
EP2200653A2 (fr) | 2007-09-10 | 2010-06-30 | University of Massachusetts | Agents antitumoraux ciblant les mitochondries |
WO2010028389A1 (fr) | 2008-09-08 | 2010-03-11 | The Methodist Hospital Research Institute | Dépôt d’énergie assisté par imagerie pour l’administration ciblée de médicaments |
WO2011116181A1 (fr) | 2010-03-17 | 2011-09-22 | Caris Life Sciences, Inc. | Procédés théranostiques et diagnostiques utilisant sparc et hsp90 |
WO2010033733A1 (fr) | 2008-09-17 | 2010-03-25 | Endocyte, Inc. | Conjugués d'antifolates liant le récepteur de folate |
WO2010056590A2 (fr) | 2008-11-14 | 2010-05-20 | University Of Maryland, Baltimore | Conjugués de traceurs d'imagerie par résonance magnétique au 19f à utiliser en imagerie irm multichrome |
WO2011020783A2 (fr) * | 2009-08-17 | 2011-02-24 | Roche Glycart Ag | Immunoconjugués ciblés |
US20110268722A1 (en) | 2010-04-22 | 2011-11-03 | Siegelin Markus D | Combination therapies with mitochondrial-targeted anti-tumor agents |
US20140031302A1 (en) | 2010-10-22 | 2014-01-30 | Universite De Strasbourg | Pochoxime conjugates useful for the treatment of hsp90 related pathologies |
WO2012096919A1 (fr) * | 2011-01-11 | 2012-07-19 | Synta Pharmaceuticals Corp. | Plurithérapie associant des composés inhibiteurs de hsp90 à des inhibiteurs du protéasome |
GB201106814D0 (en) * | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compounds |
CA2886713A1 (fr) * | 2011-10-12 | 2013-04-18 | The University Of North Carolina At Chapel Hill | Billes d'inhibiteur de kinase multiplexees et leurs utilisations |
EP2776586B1 (fr) * | 2011-11-11 | 2018-03-07 | Millennium Pharmaceuticals, Inc. | Biomarqueurs de la sensibilité vis-à-vis d'inhibiteurs du protéasome |
JP6082033B2 (ja) * | 2012-02-23 | 2017-02-15 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 置換ベンゾチエニル−ピロロトリアジンおよびその使用 |
US20140079636A1 (en) | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
CN104640572B (zh) | 2012-05-15 | 2018-04-27 | 索伦托医疗有限公司 | 药物偶联物,偶联方法,及其用途 |
CN105849086B (zh) | 2012-11-24 | 2018-07-31 | 杭州多禧生物科技有限公司 | 亲水性链接体及其在药物分子和细胞结合分子共轭反应上的应用 |
EP3738594A1 (fr) | 2013-09-10 | 2020-11-18 | Madrigal Pharmaceuticals, Inc. | Agents thérapeutiques ciblés ayant un ligand hsp90 comme moietie de liaison |
BR112016007736B1 (pt) | 2013-10-11 | 2022-09-27 | Mersana Therapeutics, Inc | Armação polimérica, e, composição farmacêutica |
RU2016134258A (ru) | 2013-10-15 | 2018-02-28 | Сорренто Терапьютикс Инк. | Конъюгат лекарственного средства с направляющей молекулой и двумя различными лекарственными средствами |
WO2015066053A2 (fr) | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Thérapies ciblées |
JP6727127B2 (ja) | 2013-12-20 | 2020-07-29 | バイオメッド バレー ディスカバリーズ,インコーポレイティド | Pi3k/aktシグナル経路阻害剤およびerk阻害剤の組み合わせを使用するがん処置 |
EP3099332A4 (fr) * | 2014-01-29 | 2017-06-21 | Madrigal Pharmaceuticals, Inc. | Agents thérapeutiques cibles |
-
2015
- 2015-03-03 MA MA039481A patent/MA39481A/fr unknown
- 2015-03-03 EP EP15758717.1A patent/EP3129064B1/fr active Active
- 2015-03-03 CN CN201580022696.0A patent/CN106456795A/zh active Pending
- 2015-03-03 WO PCT/US2015/018442 patent/WO2015134464A2/fr active Application Filing
- 2015-03-03 AU AU2015224576A patent/AU2015224576A1/en not_active Abandoned
- 2015-03-03 CA CA2941618A patent/CA2941618A1/fr not_active Abandoned
- 2015-03-03 KR KR1020167027259A patent/KR20160126078A/ko unknown
- 2015-03-03 JP JP2016555457A patent/JP6576942B6/ja not_active Expired - Fee Related
-
2016
- 2016-08-30 US US15/251,255 patent/US10232049B2/en active Active
- 2016-09-04 IL IL247624A patent/IL247624A0/en unknown
-
2018
- 2018-10-25 US US16/170,733 patent/US10675360B2/en active Active
-
2019
- 2019-08-21 JP JP2019151197A patent/JP2019196406A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3129064B1 (fr) | 2020-01-01 |
WO2015134464A2 (fr) | 2015-09-11 |
EP3129064A2 (fr) | 2017-02-15 |
US10675360B2 (en) | 2020-06-09 |
JP2017507150A (ja) | 2017-03-16 |
US10232049B2 (en) | 2019-03-19 |
US20170049899A1 (en) | 2017-02-23 |
JP6576942B6 (ja) | 2019-11-27 |
AU2015224576A1 (en) | 2016-09-22 |
WO2015134464A3 (fr) | 2015-10-29 |
JP6576942B2 (ja) | 2019-09-18 |
CN106456795A (zh) | 2017-02-22 |
US20190060478A1 (en) | 2019-02-28 |
CA2941618A1 (fr) | 2015-09-11 |
IL247624A0 (en) | 2016-11-30 |
EP3129064A4 (fr) | 2017-10-25 |
KR20160126078A (ko) | 2016-11-01 |
JP2019196406A (ja) | 2019-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FIC20240015I1 (fi) | Zilbrysq - tsilukoplaani | |
DK3132036T3 (da) | Målrettede mutationer | |
DK3183051T3 (da) | Væske-til-luftmembranenergivekslere | |
MA39481A (fr) | Thérapies ciblées | |
DK3211743T3 (da) | Ø-til-netværk-omskiftningsfremgangsmåde | |
DK3222714T3 (da) | Phytasemutanter | |
DK3119396T3 (da) | Muscarinreceptoragonister | |
DK3006072T3 (da) | Karadgang | |
DK3110442T3 (da) | Modificerede meningokok-fhbp-polypeptider | |
DE112015001664A5 (de) | Betätigungsaktuator | |
DK3183340T3 (da) | Termolabile exonukleaser | |
DK3154703T3 (da) | Fuldkappe-snekkecentrifuge | |
DK3110439T3 (da) | Pcsk9-vacciner | |
DE112015005041A5 (de) | Gargerätevorrichtung | |
DE102014000623A8 (de) | Halbhohlnietelement | |
DK3009858T3 (da) | Skyradar | |
DE112015001633A5 (de) | Betätigungsaktuator | |
DK3447493T3 (da) | Proteinrettede ortologer | |
ES1133830Y (es) | Columbario | |
DK3091875T3 (da) | Vipbar taburet | |
DE202014005655U8 (de) | llluminationsvorrichtung | |
DE112015005055A5 (de) | Gargerätevorrichtung | |
DK3191825T3 (da) | Kreatininbiosensor | |
FI10894U1 (fi) | Putkieristyskouru | |
ES1137381Y (es) | Trompo |